According to the RNC Pharma® database “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)”, in Q1–Q3 2025, Russian consumers purchased 5.7 million packs of antiarrhythmic drugs (EphMRA group C01B) in the retail market, including online sales. The physical volume of consumption increased by 11.7% year-on-year. The monetary volume of retail sales in this therapeutic group exceeded RUB 3.3 billion (retail prices, including VAT). Compared with the same period in 2024, total consumer spending in the category grew by 26.1%.

This market segment has been showing steady positive dynamics for several years: in 2024, sales volume grew by 11.5% versus 2023, while consumer spending increased by 20%.

Within the analyzed category, drugs containing lappaconitine hydrobromide remain dominant — accounting for 38% of total sales volume and over 41% in value terms in January–September 2025. Sales were recorded for five brands with this INN, two of which entered the market within the past three years. The widest representation is observed in amiodarone-based products, with 19 manufacturers active in the retail market in 2025.

Overall, during the first nine months of 2025, 17 antiarrhythmic brands from 32 companies were present in the Russian retail segment. Allapinin (produced by Pharmcenter VILAR) retained the leading position, accounting for 27.9% of total category sales in value terms. Despite its systemic importance, Allapinin showed the lowest growth rate among the top 10 brands — up 8% in ruble terms and 3% in packages versus the same period in 2024.

In second place is Etacizin by Olainfarm (Latvia), with a 25.4% share and +17% year-on-year in value. Third is Propanorm from the Czech company PRO.MED.CS, generating 18.4% of total sales and showing a +50% increase in ruble terms.

Two brands in the top 10 reported sales declines — Cordarone (Sanofi, –61%) and Lappaconitine (Yuzhpharm, –26%). The decrease in Cordarone sales is directly linked to supply disruptions: the drug last entered the Russian market in February 2025, and remaining stocks in distribution channels are nearly depleted. In September 2025, only 1.7 thousand packs were sold, compared with over 114 thousand a year earlier.

The fastest-growing brand in the segment was Fleicardil (MIR-PHARM), introduced in 2024. The brand ranked eighth, with sales rising 27.4-fold year-on-year. Another notable performer was unbranded amiodarone, produced by 16 companies (led by Organika): total sales increased 2.7 times versus the same period in 2024 — likely reflecting consumer switching from Cordarone.

Top-10 Antiarrhythmic Drug Brands (EphMRA Group C01B) by retail sales value in the Russian market, Q1–Q3 2025